Our Take
Clinical win masked by operational friction: the FDA signaled no efficacy or safety red flags, meaning the chemistry works, but manufacturing control questions will delay market entry by months.
Why it matters
Sobi now competes in gout treatment against established players while managing CMO dependencies. For patients with uncontrolled gout (roughly 200,000 in the US), approval timelines matter; for biotech investors watching CMO risk, this is a case study in supply-chain gatekeeping.
Do this week
Biotech counsel: audit your CMO qualification and control-strategy documentation now against FDA guidance on nanoparticle biologics, before you hit the CRL wall yourself.
Sobi Receives FDA Feedback on NASP Manufacturing
Swedish Orphan Biovitrum (Sobi) received a complete response letter from the US Food and Drug Administration regarding its biologics licence application for NASP (nanoencapsulated sirolimus plus pegadricase), a therapy for adults with uncontrolled gout. The FDA did not cite concerns about clinical efficacy or safety that would affect approval potential. Instead, the letter requested further information on the manufacturing control strategy of the biological component and deficiencies related to contract manufacturing facility operations.
NASP is a sequential two-component infusion administered every four weeks. It combines tolerogenic nanoencapsulated sirolimus, designed to suppress anti-drug antibodies, with pegadricase, which lowers serum uric acid levels. The therapy targets roughly 200,000 people in the US with uncontrolled gout who continue to experience high uric acid and debilitating flares despite oral therapies (company-reported patient population estimate).
Sobi stated it will request a meeting with the FDA to discuss feedback and work with contract manufacturing organisations to address the outlined deficiencies. Chief medical officer Lydia Abad-Franch said the company "continues to believe strongly in NASP's potential" and that clinical data have "demonstrated meaningful reductions in serum uric acid levels." The company characterised the FDA's feedback as providing "a clear and actionable path forward."
The Real Bottleneck Is Supply, Not Science
A complete response letter typically signals a resubmission cycle of 6 to 12 months, depending on the scope of CMO remediation required. The FDA's silence on clinical grounds is the win here: the drug works. But manufacturing control is a different problem. Nanoparticle biologics involve complex particle characterisation, stability testing, and facility controls that demand precision documentation. The fact that deficiencies landed on contract manufacturing operations (not Sobi's own labs) means the company's approval now depends on third-party operational alignment.
This matters for competitive timing. Sobi acquired Arthrosi Therapeutics in December 2025 to expand its gout portfolio. A 6+ month delay on NASP gives rivals more runway in a market where newer agents are entering. It also signals to biotech founders that CMO qualification is not a box-tick; it is a regulatory chokepoint that can stall otherwise-viable candidates.
What Biotech Teams Should Do
If you are developing a nanoparticle or complex biological with contract manufacturing partners, treat CMO control strategy as a pre-IND or early-IND conversation with the FDA, not a pre-BLA surprise. Request a Type B meeting to establish what the agency expects on particle characterisation, batch analytics, and facility readiness. Document your CMO's quality agreements and audit schedules now. The Sobi case shows that clinical data alone does not guarantee approval if manufacturing controls are uneven.
For investors and business development teams, this underscores why CMO choice and qualification timelines must be baked into clinical development timelines, not treated as a separate workstream. A six-month CMO remediation cycle is not exceptional; it is a known risk that compounds approval risk for complex biologics.